Retinal microvascular function and incidence and trajectories of clinically relevant depressive symptoms: the Maastricht Study

April C E van Gennip,Monideepa D Gupta,Alfons J H M Houben,Tos T J M Berendschot,Carroll A B Webers,Marleen M J van Greevenbroek,Carla J H van der Kallen,Annemarie Koster,Anke Wesselius,Simone J P M Eussen,Casper G Schalkwijk,Bastiaan E de Galan,Sebastian Köhler,Miranda T Schram,Coen D A Stehouwer,Thomas T van Sloten,April C. E. van Gennip,Monideepa D. Gupta,Alfons J. H. M. Houben,Tos T. J. M. Berendschot,Carroll A. B. Webers,Marleen M. J. van Greevenbroek,Carla J. H. van der Kallen,Simone J. P. M. Eussen,Casper G. Schalkwijk,Bastiaan E. de Galan,Miranda T. Schram,Coen D. A. Stehouwer,Thomas T. van Sloten

DOI: https://doi.org/10.1017/s0033291724000618

IF: 10.592

2024-03-13

Psychological Medicine

Abstract:Background Cerebral microvascular dysfunction may contribute to depression via disruption of brain structures involved in mood regulation, but evidence is limited. We investigated the association of retinal microvascular function, a proxy for microvascular function in the brain, with incidence and trajectories of clinically relevant depressive symptoms. Methods Longitudinal data are from The Maastricht Study of 5952 participants (59.9 ± 8.5 years/49.7% women) without clinically relevant depressive symptoms at baseline (2010–2017). Central retinal arteriolar equivalent and central retinal venular equivalent (CRAE and CRVE) and a composite score of flicker light-induced retinal arteriolar and venular dilation were assessed at baseline. We assessed incidence and trajectories of clinically relevant depressive symptoms (9-item Patient Health Questionnaire score ⩾10). Trajectories included continuously low prevalence (low, n = 5225 [87.8%]); early increasing, then chronic high prevalence (early-chronic, n = 157 [2.6%]); low, then increasing prevalence (late-increasing, n = 247 [4.2%]); and remitting prevalence (remitting, n = 323 [5.4%]). Results After a median follow-up of 7.0 years (range 1.0–11.0), 806 (13.5%) individuals had incident clinically relevant depressive symptoms. After full adjustment, a larger CRAE and CRVE were each associated with a lower risk of clinically relevant depressive symptoms (hazard ratios [HRs] per standard deviation [s.d.]: 0.89 [95% confidence interval (CI) 0.83–0.96] and 0.93 [0.86–0.99], respectively), while a lower flicker light-induced retinal dilation was associated with a higher risk of clinically relevant depressive symptoms (HR per s.d.: 1.10 [1.01–1.20]). Compared to the low trajectory, a larger CRAE was associated with lower odds of belonging to the early-chronic trajectory (OR: 0.83 [0.69–0.99]) and a lower flicker light-induced retinal dilation was associated with higher odds of belonging to the remitting trajectory (OR: 1.23 [1.07–1.43]). Conclusions These findings support the hypothesis that cerebral microvascular dysfunction contributes to the development of depressive symptoms.

psychiatry,psychology, clinical